Project Grant R44MH135465

Award Date 9/15/23
Completion Date 8/31/25
Dollars Obligated $2.9M
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $374,349 to the University of North Carolina at Chapel Hill to develop and optimize a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research aims to create a CRISPR-integrated mutant mouse line with an...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $251,250 to the University of Massachusetts Medical School (UMass Medical) to investigate the role of TDP-43 dysfunction in altering innate immune pathways and microglial function in models of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $460,625.00 to the University of Massachusetts Medical School (UMass Medical) to investigate the roles of the deubiquitylation pathway in regulating the subcellular localization and aggregation of TDP-43 protein, which is implicated in amyotrophic lateral sclerosis (ALS) and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $645,391 to investigate the effects of re-expressing embryonic motor neuron transcription factors on disease pathology in amyotrophic lateral sclerosis (ALS) models. The research aims to determine if restoring these developmental regulators can enhance the ability of mature motor...
The University of Wisconsin System was awarded a $427,625 Project Grant under the National Institute on Aging's Aging Research program (CFDA 93.866) to develop a conditional, humanized mouse model for studying Ubiquilin 2 (UBQLN2)-associated Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The proposed research aims to generate the UBQLN2 mouse model, evaluate its neurodegenerative phenotypes, and utilize it to investigate disease pathways related to ALS/FTD caused by...
This Federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $224,140 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on understanding the relationship between cortical hyperexcitability and the progression of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) pathology and behavioral deficits in mice. The key objectives of this 2-year research project are to: 1)...
This $1,157,896 Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research at Brown University focused on elucidating the mechanistic basis of transketolase-mediated suppression of neurodegeneration in amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD). The grantee will study multiple models of ALS/FTD using Drosophila genetics and analyze molecular readouts such as redox state, autophagy,...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

IMPLEMENTING A COUPLED SYSTEM OF INTEGRATIVE ML MODELING AND DATA VALIDATION FOR ELUCIDATING MICROGLIAL THERAPEUTIC TARGETS IN NEURODEGENERATIVE DISEASE - PROJECT SUMMARY/ABSTRACT: ALS AND FTD ARE FATAL NEURODEGENERATIVE DISEASES THAT PRESENTLY HAVE NO CURE. TO DATE, ONE FOCUS AREA IN ALS RESEARCH HAS BEEN DEVELOPING MODEL SYSTEMS TO CHARACTERIZE THE CONDITION, WITH OVER 20 DIFFERENT ALS MOUSE MODELS, AND MORE RECENTLY, NUMEROUS IPSC BASED MODELS, EACH GRADUALLY CONTRIBUTING TO OUR OVERALL KNOWLEDGE OF THE MECHANISMS BEHIND NEURODEGENERATION, AND THE CONTRIBUTION OF THE NEURO-IMMUNE INTERFACE. DESPITE THE MULTITUDE OF DISEASE MODELS, THERE IS NO OVERARCHING, COMPUTATIONAL MODELING FRAMEWORK FOR INTEGRATING DISPARATE DATASETS, TOWARDS THE GOAL OF CHARACTERIZING DISEASE NETWORKS, AND IDENTIFYING THERAPEUTIC TARGETS. MOREOVER, WHILE STANDARD ML MODELS FOR TARGET PREDICTION HAVE BECOME UBIQUITOUS IN THE BIOMEDICAL SCIENCES, THEY FAIL TO LEARN CAUSALITY, SHEDDING LITTLE INSIGHT INTO UNDERLYING DISEASE ETIOLOGY AND FAILING TO MAKE EFFECTIVE TARGET PREDICTIONS. OUR PROPOSAL'S LONG-TERM GOAL IS TO CREATE A FLEXIBLE PIPELINE, APPLICABLE TO ND DISEASES, TO CHARACTERIZE THE NEURO-IMMUNE INTERFACE AND ITS CONTRIBUTION TO ND ETIOLOGY, TO ENABLE THERAPEUTIC INTERVENTION BY CREATING AN INTEGRATED WORKFLOW TO IDENTIFY ND MICROGLIAL DISEASE NETWORKS IN HEALTH, DISEASE, AND DISEASE SUBSETS. WE WILL CAPITALIZE ON EXISTING EXPERIMENTAL DATA AS WELL AS INTERNAL IPSC BASED IN VITRO MODELS, PAIRED WITH A CAUSAL ML MODEL. EACH COMPONENT OF THIS WORKFLOW CAN WORK INDEPENDENTLY, OR CAN BE LINKED TO THE OTHER IN A POWERFUL 'ACTIVE LEARNING' FRAMEWORK, IN WHICH THE ML MODEL MAKES PREDICTIONS, THE CO-CULTURE SYSTEM VALIDATES OR DISPROVES THE PREDICTION, AND IN EACH SUCH ROUND THE IN SILICO MODEL IS REFINED BY INTEGRATING THE NEW EXPERIMENTAL DATA. OUR CAUSAL MACHINE LEARNING MODEL CHARACTERIZES ND NEURO-IMMUNE NETWORKS FROM ANALYSIS OF COMBINED MOLECULAR, CLINICAL, AND FUNCTIONAL DATA IN A MULTI-LAYERED FORMAT WITH INDIVIDUAL LAYERS FOR ND DISEASE STATE, DATA PLATFORM, AND CELL STATE ANALYZED SIMULTANEOUSLY TO BOLSTER CONFIDENCE FOR INFERENCES SHARED AMONG NUMEROUS LAYERS AND IDENTIFY UNIQUE, AND THERAPEUTICALLY RELEVANT, NETWORK ELEMENTS. WE WILL FOCUS INITIALLY ON THERAPEUTIC INTERVENTIONS FOR ALS, FOLLOWED BY RELATED ND DISEASES ALSO CHARACTERIZED IN THE NETWORK MODEL. THE OBJECTIVES OF THIS PROPOSAL ARE: (1) TO REFINE AN IN SILICO FRAMEWORK FOR DATA INTEGRATION ACROSS NDS, MICROGLIAL SUBSETS, AND HETEROGENEOUS DATASETS/DATA PLATFORMS ENABLING A ROBUST MODEL FOR THERAPEUTIC TARGET PREDICTION AND (2) TO VALIDATE PREDICTED TARGETS IN OUR IPSC MICROGLIA AND NEURON CO-CULTURE SYSTEM USING IN VITRO PERTURBATIONS (INCLUDING ANTISENSE-OLIGONUCLEOTIDES AND SMALL MOLECULES) AND HIGH-CONTENT IMAGING ANALYSIS. THE CENTRAL HYPOTHESIS IS THAT COMPREHENSIVELY INTEGRATING AVAILABLE DATA ACROSS PUBLIC DATASETS AND DATABASES, ND DISEASES, MODEL SPECIES, DATA PLATFORMS, AND TISSUE TYPES, WITH DATA FROM OUR CO-CULTURE SCREENING PLATFORM, IN A POWERFUL MECHANISTIC MODEL, WILL ENABLE ELUCIDATION OF CAUSAL DISEASE PATHWAYS, COMPARATIVE ANALYSIS ACROSS CONDITIONS, AND THE IDENTIFICATION OF THERAPEUTIC TARGETS. ULTIMATELY, CHARACTERIZATION OF INDIVIDUALS CAN EVEN ENABLE PERSONALIZED THERAPY APPROACHES AS WELL AS IDENTIFICATION OF DISEASE SUBTYPES. 1

Posted 9/15/23, 12:00 AM